Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)

Phase 3

Completed

Conditions: Atopic Dermatitis Eczema

Interventions: Drug: ARQ-151 Active
Drug: ARQ-151 Vehicle

Registration Number: NCT04845620

Lead Sponsor: Arcutis Biotherapeutics, Inc.

Brief Summary: This study will assess the safety and efficacy of ARQ-151 cream vs vehicle applied once a day for 4 weeks by subjects with atopic dermatitis (eczema).

Detailed Description: This is a parallel group, double blind, vehicle-controlled study in which ARQ-151 cream or vehicle is applied once daily for 4 weeks to subjects with atopic dermatitis.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 652

Inclusion Criteria

Informed consent by parent(s) or legal guardian as required by local laws.
Males and females, ages 2 to 5 years old at time of signing Informed Consent (Screening) and at Baseline (Day 1).
Diagnosed with atopic dermatitis for at least 6 weeks, as determined by the Investigator. Stable disease for the past 4 weeks with no significant flares in atopic dermatitis before screening.
In good health as judged by the Investigator.
Subjects considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator.

Exclusion Criteria

Subjects with any serious medical condition or clinically significant abnormality that would prevent study participation or place the subject at significant risk, as judged by the Investigator
Has unstable AD or any consistent requirement for high potency topical steroids.
Subjects who are unwilling to refrain from prolonged sun exposure for 4 weeks prior to Baseline/Day 1 and during the study.
Previous treatment with ARQ-151.
Parent(s)/legal guardian(s) who are unable to communicate, read, or understand the local language(s). Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.
Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members of enrolled (in other studies of ARQ-151) subjects living in the same house.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
ARQ-151 Cream 0.05%	ARQ-151 Active	Active comparator
ARQ-151 Vehicle Cream	ARQ-151 Vehicle	Placebo comparator

Primary Outcome Measures

Name	Time	Method
IGA Success, defined as a vIGA-AD score of 'clear' or 'almost clear' PLUS a 2-grade improvement from Baseline at Week 4.	Week 4	The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear).

Secondary Outcome Measures

Name	Time	Method
In subjects with vIGA-AD score of 'Moderate' at randomization, IGA Success at Week 4	Week 4	IGA Success, defined as a vIGA-AD score of 'clear' or 'almost clear' PLUS a 2-grade improvement from Baseline. The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear).
In subjects with vIGA-AD score of 'Moderate' at randomization, achievement of at least 75% reduction in the Eczema Area and Severity Index (EASI-75) at Week 4	Week 4	EASI combines the assessment of the severity of lesions and the area affected into a single total score in the range 0 (no disease) to 72 (maximal disease). To calculate the EASI, the sum of the severity rating (0 to 3 with 3 being the most severe) for four clinical signs are multiplied with the numerical value of the area affected and with the percentage of the four body areas.
In subjects with vIGA-AD score of 'Moderate' at randomization, vIGA-AD score of 'clear' or 'almost clear' at Week 4	Week 4	The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear).
vIGA-AD success at Week 2	Week 2	The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear).
vIGA-AD of 'clear' or 'almost 'clear' at Week 2	Week 2	The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear).
vIGA-AD success at Week 1	Week 1	The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear).
vIGA-AD of 'clear' or 'almost 'clear' at Week 1	Week 1	The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear).

Trial Locations

Locations (75): Arcutis Clinical Site 56
🇺🇸
Birmingham, Alabama, United States
Arcutis Clinical Site 14
🇺🇸
Birmingham, Alabama, United States
Arcutis Clinical Site 69
🇺🇸
Montgomery, Alabama, United States
Arcutis Clinical Site 68
🇺🇸
Gilbert, Arizona, United States
Arcutis Clinical Site 26
🇺🇸
Scottsdale, Arizona, United States
Arcutis Clinical Site 50
🇺🇸
Bryant, Arkansas, United States
Arcutis Clinical Site 59
🇺🇸
Fort Smith, Arkansas, United States
Arcutis Clinical Site 71
🇺🇸
Little Rock, Arkansas, United States
Arcutis Clinical Site 09
🇺🇸
Inglewood, California, United States
Arcutis Clinical Site 45
🇺🇸
Rancho Santa Margarita, California, United States
Scroll for more (65 remaining)
Arcutis Clinical Site 56
🇺🇸Birmingham, Alabama, United States